




Data Featured at UEGW 2026

Johnson&Johnson

United European
Gastroenterology Week

Barcelona, Spain
October 17–20, 2026

J&J Sponsored R&D Studies

Abstract numbers	Title	Presentation time (CEST)
<i>Guselkumab studies</i>		
<i>FUZION study – Late-breaker</i>		
LB09	Efficacy and safety of guselkumab in perianal fistulizing Crohn's disease: week 48 results from the Phase 3, randomized, double-blind, placebo-controlled FUZION trial	Monday, October 19 10:00 a.m.

<i>GALAXI studies</i>		
Podium Presentations		
OP105*	Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: results through week 144 from the phase 3 GALAXI 2 & 3 studies	Monday, October 19 11:40 – 11:50 a.m.
OP106*	Deep remission in guselkumab-treated participants with moderately to severely active Crohn's disease through 3 years: results from the GALAXI 2 & 3 studies	Monday, October 19 11:50 a.m. – 12:00 p.m.
Moderated Posters		
MP0299	Guselkumab efficacy in subgroups of adults with a history of inadequate response or intolerance to anti-tumor necrosis factor- α therapy and moderately to severely active Crohn's disease: results from the GALAXI 2 & 3 studies	Sunday, October 18 5:48 – 5:54 p.m.
MP0081	Early improvement of inflammatory biomarkers predicts 1-year outcomes in adults with Crohn's disease treated with guselkumab: pooled GALAXI 2 & GALAXI 3, Phase 3 trials analysis	Sunday, October 18 10:30 – 10:36 a.m.
MP0993*	Endoscopic outcomes of ulcer size and ulcerated surface over one year across bowel segments in participants with Crohn's disease treated with guselkumab: pooled GALAXI 2 & GALAXI 3, Phase 3 trials analysis	Tuesday, October 20 1:24 – 1:30 p.m.
e-Poster		
PP1190	Regulation of fibroblast biology in ileum and rectum with guselkumab in Crohn's disease: post-hoc analysis of GALAXI Phase 3 program	Saturday, October 17

<i>GALAXI/GRAVITI studies</i>		
Moderated Posters		
MP0083*	Changes in intestinal stenosis among patients with moderately to severely active Crohn's disease treated with guselkumab: results from the Phase 3 GALAXI & GRAVITI studies	Sunday, October 18 10:42 – 10:48 a.m.
MP0229*	Pharmacokinetics and exposure-response relationships of subcutaneous guselkumab maintenance in participants with moderately to severely active Crohn's disease	Sunday, October 18 4:24 – 4:30 p.m.

<i>QUASAR/ASTRO studies</i>		
Podium Presentation		
OP243*	Pharmacokinetics and exposure-response relationships of subcutaneous guselkumab maintenance in participants with moderately to severely active ulcerative colitis	Tuesday, October 20 10:00 – 10:10 a.m.

<i>ASTRO study</i>		
Moderated Poster		
MP0297*	The efficacy and safety of guselkumab in patients with moderate to severe ulcerative colitis through 2 years: ASTRO week 96 results	Sunday, October 18 5:42 – 5:48 p.m.
e-Poster		
PP1354*	Unsupervised machine learning to identify distinct patient-level response patterns to guselkumab in ulcerative colitis: post hoc analysis from the ASTRO trial	Saturday, October 17

<i>Icotrokinra studies</i>		
<i>ANTHEM study</i>		
Podium Presentation		
OP194*	Histologic and endoscopic efficacy of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in ulcerative colitis: outcomes from the ANTHEM-UC study	Tuesday, October 20 8:30 – 8:40 a.m.
Moderated Poster		
MP0911	Single-cell and spatial profiling of cellular composition and signaling changes following icotrokinra treatment in ulcerative colitis: results from ANTHEM-UC	Tuesday, October 20 11:42 – 11:48 a.m.
e-Poster		
PP1193	Plasma, colon tissue and fecal pharmacokinetics of icotrokinra in ulcerative colitis: results from a Phase 2b dose-ranging study	Saturday, October 17

<i>JNJ-4804 studies</i>		
<i>DUET-UC study</i>		
Podium Presentation		
OP255*	Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active ulcerative colitis refractory to two or more systemic therapy mechanisms	Tuesday, October 20 11:30 – 11:40 a.m.

<i>DUET-CD study</i>		
Moderated Poster		
MP0562*	Efficacy and safety of the first co-antibody therapy, JNJ-78934804, in patients with moderately to severely active Crohn's disease refractory to two or more systemic therapy mechanisms	Monday, October 19 1:12 – 1:18 p.m.

<i>Ustekinumab studies</i>		
<i>UNIFI Jr. study</i>		
e-Poster		
PP1353	Assessment of inflammatory bowel disease-specific quality of life (IMPACT-III) symptoms after treatment with ustekinumab in pediatric ulcerative colitis	Saturday, October 17

<i>AI studies</i>		
<i>ARGES study</i>		
Moderated Poster		
MP0771	ARGES 2.0: artificial intelligence-derived endoscopic severity scoring and disease characterization in ulcerative colitis	Tuesday, October 20 8:42 – 8:48 a.m.

<i>ARGES/UNIFI Jr. study</i>		
e-Poster		
PP1197	Computer-vision assessment of endoscopic disease severity in subjects with and without prior exposure to advanced therapies across adult and pediatric ulcerative colitis clinical trials	Saturday, October 17

Market Access and Real-World Evidence

Abstract Numbers	Title	Presentation time (CEST)
<i>Retrospective study</i>		
e-Poster		
PP1411	Association of endoscopic healing with clinical outcomes in inflammatory bowel disease: a retrospective study	Saturday, October 17

<i>Physician survey</i>		
Moderated Poster		
MP0282	Imaging practices and use of intestinal ultrasound for moderate-to-severe inflammatory bowel disease: a multinational physician survey in China, Japan, and Germany	Sunday, October 18 5:12 – 5:18 p.m.
e-Posters		
PP1312	Physician opinions on treatment preferences and long-term treatment goals for moderate-to-severe inflammatory bowel disease in China, Japan, and Germany	Saturday, October 17
PP1433	Physician opinions on treatment preferences and long-term treatment goals in moderate to severe ulcerative colitis and Crohn's disease in Germany	Saturday, October 17

<i>GORGEOUS study</i>		
e-Poster		
PP1357	Early symptomatic response to guselkumab in inflammatory bowel disease: first real-world data from the German GORGEOUS study	Saturday, October 17

<i>DUMBO study</i>		
Moderated Poster		
MP0431	Ustekinumab exposure during pregnancy and risk of small for gestational age in inflammatory bowel disease: results from the DUMBO registry of GETECCU	Monday, October 19 10:06 – 10:12 a.m.

Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling